Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
MREO Mereo BioPharma
- 3.7400
- +0.0100+0.27%
Close Dec 13 16:00 ET
- 3.7600
- +0.0200+0.53%
Post 16:00 ET
580.24MMarket Cap-12.47P/E (TTM)
3.7800High3.6300Low619.99KVolume3.7100Open3.7300Pre Close2.30MTurnover0.62%Turnover RatioLossP/E (Static)155.15MShares5.020052wk High7.99P/B375.51MFloat Cap1.970052wk Low--Dividend TTM100.40MShs Float8.4800Historical High--Div YieldTTM4.02%Amplitude0.3010Historical Low3.7150Avg Price1Lot Size
About Mereo BioPharma Company
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Company Profile
SymbolMREO
Company NameMereo BioPharma
Listing DateApr 24, 2019
Issue Price17.62
Founded2015
CEODr. Denise Vera Scots-Knight, PhD
MarketNASDAQ
Employees33
Securities TypeDR
ADS Ratio1.0 : 5.0
Fiscal Year Ends12-31
Address1 Cavendish Place,4th Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1G 0QF
Phone44-333-023-7300
Company Executives
- Name
- Position
- Salary
- Dr. Denise Vera Scots-Knight, PhD
- Executive Director,Chief Executive Officer
- 2.22M
- Michael Stephen Wyzga
- Non-Executive Director,Chairman
- 156.80K
- Pierre Jacquet
- Non-Executive Director
- 102.18K
- Dr. Annalisa Mary Jenkins
- Non-Executive Director
- 100.96K
- Dr. Jeremy Bender
- Non-Executive Director
- 105.08K
- Justin Roberts
- Non-Executive Director
- --
- Dr. Deepika Rachel Pakianathan
- Non-Executive Director
- 113.76K
- Dr. Anders Olof Adolf Ekblom
- Non-Executive Director
- 121.31K
- Marc J. Yoskowitz
- Non-Executive Director
- 94.49K
- Daniel Shames
- Non-Executive Director
- 97.75K
- Charles Sermon
- General Counsel & Company Secretary
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.